PhD Thesis – Therapy for Huntington's Disease

The Fraunhofer Society currently operates 74 institutes and research units throughout Germany and is a leading applied research organization. Around 32 000 employees work with an annual research budget of 3.4 billion euros. The Fraunhofer Institute for Translational Medicine and Pharmacology ITMP researches and develops innovative methods for the early detection, diagnosis, and treatment of diseases resulting from impaired immune system functions. We see ourselves as a strong partner to university medicine for the consistent translation of research findings into application, as well as to the pharmaceutical and biotechnology industry for the application of the latest findings from science and research to specific projects. One of our projects aims to innovate therapeutic advancements for Huntington's disease, a fatal neurodegenerative disorder that affects the glymphatic and lymphatic systems, which are critical for removing the waste products of brain cells. Major symptoms include motor dysfunction, cognitive decline, and neurological issues. Currently, there is neither a known treatment to delay Huntington's disease onset nor sufficient digital tools to

---